Abivax's KOL Investor Webinar: Odefazimod's Phase 2b Data and Phase 3 UC Trial Insights

On January 24, 2024, Abivax SA, a clinical-stage biotechnology firm, announced its plan to host a virtual KOL Investor Event on February 6, 2024. The event, scheduled for 2:00 p.m. EST, will be centered around the company's lead drug candidate, obefazimod, and its clinical development for treating patients with ulcerative colitis (UC). The company aims to discuss the unmet needs and current treatment landscape for UC patients and will feature presentations by Marla Dubinsky, MD, and Parambir Dulai, MD, alongside Abivax’s management.

Obefazimod is an orally administered small molecule with a unique mechanism of action that increases the expression of miR-124, a key regulator in controlling inflammation. The virtual event will delve into the drug's mechanism, phase 2b clinical data, and the design of the upcoming phase 3 trials for moderately to severely active UC patients. Following the presentations, a live Q&A session will be held to address any queries from the attendees.

Marla C. Dubinsky, MD, is a renowned expert in pediatric gastroenterology and nutrition, holding a professorship at the Icahn School of Medicine at Mount Sinai in New York. She is also the Chief of the Pediatric GI and Nutrition Division at Mount Sinai Kravis Children’s Hospital. Parambir S. Dulai, MD, is an Associate Professor of Medicine at Northwestern University, with a focus on gastroenterology and hepatology. He is also the Director of GI Clinical Trials and Precision Medicine, and the Director of the Digestive Health Foundation Biorepository.

Abivax, with a presence in both France and the US, is committed to developing therapeutics that leverage the body's natural regulatory systems to modulate the immune response in chronic inflammatory diseases. The company's lead candidate, obefazimod, is currently in phase 3 trials for UC treatment.

The event is a significant step for Abivax as it showcases its commitment to addressing the challenges faced by UC patients and the medical community in finding effective treatments. It also highlights the company's dedication to advancing obefazimod through rigorous clinical trials to potentially offer a new therapeutic option for those suffering from this debilitating condition.